AU2002320828B2 - Treatment or prophylaxis of insulin-producing cell graft rejection - Google Patents

Treatment or prophylaxis of insulin-producing cell graft rejection Download PDF

Info

Publication number
AU2002320828B2
AU2002320828B2 AU2002320828A AU2002320828A AU2002320828B2 AU 2002320828 B2 AU2002320828 B2 AU 2002320828B2 AU 2002320828 A AU2002320828 A AU 2002320828A AU 2002320828 A AU2002320828 A AU 2002320828A AU 2002320828 B2 AU2002320828 B2 AU 2002320828B2
Authority
AU
Australia
Prior art keywords
insulin
macrocyclic lactone
antibody
acceptable salt
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002320828A
Other languages
English (en)
Other versions
AU2002320828A1 (en
Inventor
Philip Lake
Claudy Mullon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2002320828A1 publication Critical patent/AU2002320828A1/en
Application granted granted Critical
Publication of AU2002320828B2 publication Critical patent/AU2002320828B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AU2002320828A 2001-06-08 2002-06-07 Treatment or prophylaxis of insulin-producing cell graft rejection Ceased AU2002320828B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29706901P 2001-06-08 2001-06-08
US60/297,069 2001-06-08
PCT/EP2002/006278 WO2002100148A2 (en) 2001-06-08 2002-06-07 Treatment or prophylaxis of insulin-producing cell graft rejection

Publications (2)

Publication Number Publication Date
AU2002320828A1 AU2002320828A1 (en) 2003-05-15
AU2002320828B2 true AU2002320828B2 (en) 2006-02-02

Family

ID=23144725

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002320828A Ceased AU2002320828B2 (en) 2001-06-08 2002-06-07 Treatment or prophylaxis of insulin-producing cell graft rejection

Country Status (18)

Country Link
US (5) US20030003099A1 (enExample)
EP (1) EP1429845B1 (enExample)
JP (1) JP4476623B2 (enExample)
CN (1) CN1524002A (enExample)
AT (1) ATE424893T1 (enExample)
AU (1) AU2002320828B2 (enExample)
BR (1) BR0209319A (enExample)
CA (1) CA2445605A1 (enExample)
DE (1) DE60231522D1 (enExample)
ES (1) ES2322442T3 (enExample)
IL (1) IL158384A0 (enExample)
NO (1) NO20035434D0 (enExample)
NZ (1) NZ529044A (enExample)
PL (1) PL364359A1 (enExample)
PT (1) PT1429845E (enExample)
RU (1) RU2003136730A (enExample)
WO (1) WO2002100148A2 (enExample)
ZA (1) ZA200307893B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4318921B2 (ja) * 2001-02-22 2009-08-26 ノバルティス アクチエンゲゼルシャフト 移植片の機能発現遅延の処置のための医薬の製造のためのリンパ球ホーミング促進剤の使用
EP2338511A3 (en) * 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
CN101905023B (zh) * 2004-07-16 2012-07-11 杏林制药株式会社 有效的医药使用方法及与副作用发生的防御相关的方法
EP2384749A1 (en) * 2004-11-29 2011-11-09 Novartis AG Dosage regimen of an S1P receptor agonist
AU2006212866A1 (en) * 2005-02-08 2006-08-17 Novartis Ag Antilymphocyte antibody induction by combination of an S1P receptor agonist/modulator and of immunosuppressive drugs
WO2006124375A2 (en) * 2005-05-11 2006-11-23 Loma Linda University Substances, compositions and methods for preventing and treating immune-mediated inflammatory disorders
US20090191218A1 (en) 2005-05-11 2009-07-30 Fengchun Li DNA Vaccines And Methods For The Prevention Of Transplantation Rejection
RU2433117C2 (ru) 2005-12-15 2011-11-10 Мицубиси Танабе Фарма Корпорейшн Аминное соединение и его применение в медицинских целях
BRPI0708424A2 (pt) * 2006-03-02 2011-05-31 Alexion Pharma Inc prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento
WO2008039980A2 (en) * 2006-09-28 2008-04-03 Loma Linda University Apoptotic cell-mediated transfection of mammalian cells with interfering rna
JP5452237B2 (ja) 2008-02-07 2014-03-26 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
AU2009223148B2 (en) * 2008-03-12 2013-03-14 Loma Linda University DNA vaccines and methods for the prevention of transplantation rejection
CA2716448A1 (en) 2008-03-17 2009-09-24 Patrick Brossard Dosing regimen for a selective s1p1 receptor agonist
JP2012508215A (ja) * 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
CN104788325A (zh) * 2008-11-11 2015-07-22 诺华股份有限公司 芬戈莫德的结晶形式
CA2766944C (en) * 2009-06-30 2019-10-29 Lifescan, Inc. Analyte testing methods and device for calculating basal insulin therapy
CA2766870A1 (en) * 2009-06-30 2011-01-06 Lifescan Scotland Limited Systems for diabetes management and methods
CN103976741B (zh) * 2009-09-29 2017-02-22 生命扫描苏格兰有限公司 用于糖尿病管理的被分析物测试方法和装置
CN102770868B (zh) * 2010-02-25 2017-02-22 生命扫描苏格兰有限公司 具有高低血糖趋势通知的分析物测试方法和系统
WO2013044177A2 (en) 2011-09-23 2013-03-28 Loma Linda University Bacterial strains expressing methylase genes and uses thereof
US11680273B2 (en) 2011-09-23 2023-06-20 Loma Linda University Treatment of autoimmune diseases
CN114306643A (zh) * 2021-11-30 2022-04-12 中国科学院昆明动物研究所 一种恒河猴免疫抑制模型的构建方法及在car-t细胞植活上的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952316A (en) * 1992-10-21 1999-09-14 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
US6004565A (en) * 1997-09-02 1999-12-21 Yoshitomi Pharmaceutical Industries, Ltd. Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
CA2184356A1 (en) * 1994-03-03 1995-09-08 Russell P. Rother Terminal complement inhibitor fusion genes and proteins
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
JP4318921B2 (ja) * 2001-02-22 2009-08-26 ノバルティス アクチエンゲゼルシャフト 移植片の機能発現遅延の処置のための医薬の製造のためのリンパ球ホーミング促進剤の使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952316A (en) * 1992-10-21 1999-09-14 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
US6004565A (en) * 1997-09-02 1999-12-21 Yoshitomi Pharmaceutical Industries, Ltd. Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties

Also Published As

Publication number Publication date
JP4476623B2 (ja) 2010-06-09
JP2004534788A (ja) 2004-11-18
US20110236382A1 (en) 2011-09-29
EP1429845A2 (en) 2004-06-23
CA2445605A1 (en) 2002-12-19
ATE424893T1 (de) 2009-03-15
DE60231522D1 (de) 2009-04-23
NO20035434D0 (no) 2003-12-05
PT1429845E (pt) 2009-06-15
US20030003099A1 (en) 2003-01-02
CN1524002A (zh) 2004-08-25
US20080199465A1 (en) 2008-08-21
EP1429845B1 (en) 2009-03-11
US20060153842A1 (en) 2006-07-13
NZ529044A (en) 2008-03-28
RU2003136730A (ru) 2005-05-20
IL158384A0 (en) 2004-05-12
ZA200307893B (en) 2004-09-06
BR0209319A (pt) 2004-07-20
US20140093502A1 (en) 2014-04-03
WO2002100148A3 (en) 2004-04-22
ES2322442T3 (es) 2009-06-22
WO2002100148A2 (en) 2002-12-19
PL364359A1 (en) 2004-12-13

Similar Documents

Publication Publication Date Title
US20110236382A1 (en) Immunosuppressive combination and its use in the treatment or prophylaxis of insulin-producing cell graft rejection
AU2002320828A1 (en) Treatment or prophylaxis of insulin-producing cell graft rejection
Ochiai et al. Studies of the effects of FK506 on renal allografting in the beagle dog
CN1146411C (zh) 1,3-丙二醇衍生物的新用途
KR100634847B1 (ko) 췌장도 조직 이식을 위한 ｃｄ154 차단 요법
US20080015261A1 (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
AU2004226807B2 (en) Parenteral formulation of mycophenolic acid, a salt or prodrug thereof
CN120283040A (zh) 用于1型糖尿病治疗的具有免疫调节剂、dyrk1a抑制剂和glp1r激动剂的组合疗法
WO2000030679A1 (en) Cd25 binding molecules for use in the treatment of manifestations of rejection in transplantation
TZE et al. HUMAN ISLET XENOGRAFT SURVIVAL IN DIABETIC RATS A FUNCTIONAL AND IMMUNOHISTOCHEMICAL STUDY
JPS62190123A (ja) 免疫抑制剤
EP0430983B1 (en) Use of castanospermine as an anti-inflammatory and immunosuppressant agent
SPRANGERS et al. 20 Other Forms of
HK1060855B (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
JP5727167B2 (ja) Ｎｃｘを標的とした単離膵島ならびに移植膵島障害の新規制御法
AU2008200659A1 (en) Parenteral formulation of mycophenolic acid, a salt or prodrug thereof
WO2006005620A1 (en) Use of manzamines in transplantation and autoimmune diseases
Qian et al. PG695 IS EFFECTIVE AS A MONOTHERAPY AND ACTS SYNERGISTICALLY WITH FK506. PART I: PROLONGING RENAL ALLOGRAFT SURVIVAL IN NON-HUMAN PRIMATES.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired